Teva Announces Chief Medical Officer Transition

Company Teva Pharmaceutical Industries Event Type CMO and R&D leadership departure (previously missed 18 Nov release) Modality Not applicable Asset Not applicable Target Not applicable Disease Area Neurology and immunology pipeline Summary Teva disclosed November 18 that Eric Hughes, EVP Global R&D and chief medical…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *